CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that SYS6010 (a humanised monoclonal antibody drug conjugate targeting EGFR) (the "**Product**"), independently developed by the Group, has recently been granted another Breakthrough Therapy Designation by the National Medical Products Administration ("**NMPA**") of the People's Republic of China. The proposed indication is for use as a monotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma who have failed prior treatment with platinum-based chemotherapy and immunotherapy (the "**Indication**").

According to GLOBOCAN 2022 published by the International Agency for Research on Cancer (IARC), esophageal cancer is a highly prevalent gastrointestinal malignancy globally, among which esophageal squamous cell carcinoma is the predominant pathological subtype, accounting for more than 90% of cases in high-incidence regions such as China. China has a high incidence of esophageal squamous cell carcinoma, and the disease burden is extremely heavy. Furthermore, data on the burden of malignant tumours in China in 2022 released by the National Cancer Center showed that esophageal squamous cell carcinoma ranks seventh in incidence among all malignancies in China, with up to 224,000 new cases and approximately 188,000 deaths annually. Both new cases and deaths account for approximately half of the global total.

At present, platinum-based chemotherapy in combination with immunotherapy has become the first-line standard treatment for advanced esophageal squamous cell carcinoma. Nevertheless, subsequent treatment options remain limited for relapsed or refractory patients who have failed this regimen. These patients rely solely on traditional chemotherapeutic agents such as docetaxel and irinotecan, which yield a relatively low overall objective response rate (ORR) and a relatively short median overall survival (mOS). The efficacy is limited and the prognosis is poor, representing a substantial unmet clinical need.

Clinical studies of the Product for the Indication have demonstrated breakthrough efficacy. Compared to the existing standard treatment for relapsed esophageal cancer, it is expected to bring more significant clinical benefits, coupled with a favourable safety profile and relatively clear clinical advantages. At this stage, the Group has officially initiated and is fully accelerating the progress of the Phase III confirmatory clinical study of the Product for the indication of esophageal squamous cell carcinoma; meanwhile, multiple Phase III clinical studies for various solid tumour indications, including the first-line treatment of non-small cell lung cancer, the second-line treatment of non-small cell lung cancer, and the second-line and beyond treatment of breast cancer, are also being conducted simultaneously. Previously, the Product was granted Breakthrough Therapy Designation by the NMPA in January 2025 for the indication of EGFR-mutant resistant non-small cell lung cancer.

The granting of Breakthrough Therapy Designation to the Product for the indication of esophageal squamous cell carcinoma will help accelerate the overall clinical development and regulatory review and approval process across multiple solid tumour indications, expediting market launch. This will provide a novel and highly effective treatment option for patients with advanced tumours, while continuously optimising the Group's pipeline layout in the therapeutic area of oncology, and consolidating and enhancing the Group's differentiated R&D capabilities and competitive market advantages in the field of antibody-drug conjugates.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 11 May 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.